ESMO 2021 | ESMO 2021 breast cancer highlights: TULIP and KEYNOTE-355
Javier Cortés, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, discusses the results from two key trials presented at ESMO: TULIP (NCT03262935) and KEYNOTE-355 (NCT02819518). TULIP evaluates the efficacy of an antibody-drug conjugate (ADC), trastuzumab duocarmazine versus the physician’s drug choice. Whilst the primary endpoint was met, with a progression-free survival (PFS) of 7 months for patients treated with trastuzumab duocarmazine, in comparison to 4.9 months for patients treated with the physician’s drug choice, 78% of patients experienced high-grade toxicity. Moreover, the KEYNOTE-355 study compared first-line treatment with chemotherapy plus pembrolizumab versus chemotherapy plus placebo in patients with triple-negative breast cancer and demonstrated a statistically significant improvement in PFS and overall survival (OS) for patients treated with pembrolizumab plus chemotherapy. These results support the use of this combination therapy for PD-L1-positive patients with triple-negative breast cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
Disclosures
Dr Cortes reports consulting/advisor: Roche , Celgene, Cellestia, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Merck Sharp&Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab, Gilead, Menarini.
Dr Cortes reports honoraria: Roche , Novartis , Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp&Dohme, Daiichi Sankyo.
Dr Cortes reports research funding to the Institution: Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F.Hoffman-La Roche, Guardanth health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Puma C, Queen Mary University of London.
Dr Cortes reports stock, patents and intellectual property: MedSIR
Dr Cortes reports travel, accommodation, expenses: Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo
